Canadian Guidelines on HIV Pre-exposure Prophylaxis and Non-Occupational Post Exposure Prophylaxis:
Darrell H. S. Tan, Mark W. Hull, Deborah Yoong, Cécile Tremblay, Patrick O’Byrne, Réjean Thomas, Julie Kille, Jean-Guy Baril, Joseph Cox, Pierre Giguere, Marianne Harris, Christine Hughes, Paul MacPherson, Shannon O’Donnell, Joss Reimer, Ameeta Singh, Lisa Barrett, Isaac Bogoch, Jody Jollimore, Gilles Lambert, Bertrand Lebouche, Gila Metz, Tim Rogers and Stephen Shafran; for the Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network.
CMAJ November 27, 2017 189 (47) E1448-E1458; DOI: https://doi.org/10.1503/cmaj.170494
- Pre-exposure prophylaxis (PrEP) involving daily tenofovir disoproxil fumarate/emtricitabine 300/200 mg, taken orally, is a highly effective strategy for reducing the risk of HIV acquisition in adults who are at high, ongoing risk of infection.
- In gay, bisexual and other men who have sex with men with frequent exposures, an on-demand regimen may also be considered.
- Nonoccupational postexposure prophylaxis (nPEP) involving 28 days of antiretroviral medications is an effective strategy for reducing the risk of HIV acquisition from a recent (within 72 h) incident of moderate or high-risk exposure to HIV.
- PrEP and nPEP should be part of a combination prevention strategy that includes behavioural interventions, such as condoms and counselling on risk reduction.
URL for full guidelines
For more information on prescribing PrEP See CTN 303’s CME module:
To find out if PrEP is right for you see the patient module:
The Canadian HIV-HCV Co-infection Guidelines list 53 specific recommendations for:
- Evaluating co-infected patients
- Addressing barriers to care
- Selecting treatments
- Determining treatment timing
- Addressing drug-to-drug interactions.
The Canadian HIV Pregnancy Guidelines list 24 specific recommendations for:
- Antenatal care
- Intrapartum care
- Postpartum care
Dr. Hudson Reddon, CTN Postdoctoral Fellow, discusses his project which aims to describe the effect of cannabis legalization on injection drug use and HIV risk.
The 10th International AIDS Society Conference on HIV Science – known as IAS 2019 – will take place on July…
Investment will support research on prevention, treatment, and developing a cure for HIV.
Today, more than half of all people living with HIV in Canada are 50 years or older. This is mostly because people are living much longer, healthier lives with HIV thanks to the success of antiretroviral therapy (ART).